Search
Eli Lilly and Co
LLYAdd to Watchlist
1098.570USD
-13.820-1.24%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.04TMarket Cap
38.96P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Eli Lilly and Co is 8.11, ranking 54 out of 157 in the Pharmaceuticals industry. The average price target is 1055.00, with a high of 1500.00 and a low of 706.04.
Analyst Rating
Based on
35
analysts
Buy
Current Rating
1208.233
Target Price
+8.65%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Eli Lilly and Co
LLY
35
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
Gilead Sciences Inc
GILD
33
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Eli Lilly and Co's expected revenue for the next quarter?
Eli Lilly and Co's expected revenue is 20.32B.
What is Eli Lilly and Co's price target?
Analysts forecast that Eli Lilly and Co's price target is USD 1.05K, with the highest forecast at USD 1.50K and the lowest forecast at USD 706.04.
How have Eli Lilly and CoLLY's recent earnings per share performed?
The market expectation was USD 8.27, while Eli Lilly and CoLLY's earnings per share (EPS) for the previous quarter was USD 7.41. EPS for the next quarter is expected at USD 8.81.
What is the analyst rating for Eli Lilly and Co?
Based on the ratings of Eli Lilly and Co's stock from 35 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
